Market Entry Strategy

UroPharma’s initial strategy is to bring dtb therapeutics to people with MS in the US, UK and Europe

UroPharma’s own market research indicates that many people with Multiple Sclerosis MS (who are already self-catheterizing) will choose dtb therapy throughout their lives because of its effectiveness and minimal side effect profile, which translates to a potential recurring revenue stream for UroPharma.

Contact Us

Tel: +44 (0) 1603 626 960


Social Media

  • LinkedIn Social Icon

  • Twitter

  • Facebook

©2017-2020 UroPharma, Inc. All Rights Reserved